XOMA Co. (NASDAQ:XOMA) Receives Consensus Rating of “Hold” from Brokerages

XOMA Co. (NASDAQ:XOMAGet Rating) has been given a consensus recommendation of “Hold” by the six analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $49.00.

XOMA has been the subject of several research reports. StockNews.com downgraded XOMA from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. HC Wainwright reaffirmed a “buy” rating and set a $69.00 price target on shares of XOMA in a report on Monday, May 2nd. Finally, TheStreet raised XOMA from a “c-” rating to a “b-” rating in a report on Friday, April 1st.

NASDAQ XOMA opened at $17.26 on Wednesday. XOMA has a 52-week low of $16.96 and a 52-week high of $39.02. The business has a 50 day simple moving average of $23.21 and a 200 day simple moving average of $22.47. The stock has a market cap of $197.13 million, a price-to-earnings ratio of 32.57 and a beta of 1.09.

XOMA (NASDAQ:XOMAGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. The company had revenue of $3.11 million during the quarter, compared to the consensus estimate of $3.56 million. XOMA had a return on equity of 8.77% and a net margin of 27.35%. Analysts anticipate that XOMA will post -0.33 EPS for the current fiscal year.

In other XOMA news, CFO Thomas M. Burns sold 2,339 shares of XOMA stock in a transaction that occurred on Tuesday, March 22nd. The stock was sold at an average price of $30.02, for a total value of $70,216.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James R. Neal sold 50,000 shares of XOMA stock in a transaction that occurred on Monday, March 21st. The stock was sold at an average price of $29.00, for a total value of $1,450,000.00. The disclosure for this sale can be found here. Insiders sold 53,450 shares of company stock worth $1,553,569 in the last 90 days. 10.90% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG increased its holdings in shares of XOMA by 23.5% during the first quarter. UBS Group AG now owns 3,632 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 691 shares in the last quarter. Citigroup Inc. increased its holdings in shares of XOMA by 118.0% during the fourth quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of XOMA by 138.5% during the third quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 834 shares in the last quarter. State Street Corp increased its holdings in shares of XOMA by 1.1% during the first quarter. State Street Corp now owns 131,340 shares of the biotechnology company’s stock valued at $3,675,000 after acquiring an additional 1,464 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of XOMA by 78.5% during the second quarter. Wells Fargo & Company MN now owns 3,774 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 1,660 shares in the last quarter. Hedge funds and other institutional investors own 56.11% of the company’s stock.

XOMA Company Profile (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Further Reading

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.